ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1120

Interleukin-1β Stabilize CXCL2 mRNA and Increase Its Expression

Satoshi Yamasaki, Yusuke Yoshida and Eiji Sugiyama, Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: chemokines, cytokines and metabolism, IL-1, RNA

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis - Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Changes in gene expression are closely related to inflammation and joint destruction in RA. Recently, it has been recognized that post-transcriptional regulation of the gene expression of various cytokines is important to the immunological process. In this study, we attempted to identify cytokines that regulate the metabolism of RA-related mRNA through unique AU rich elements (ARE), which are characterized by AUUUA repeats in their 3′ untranslated regions (3′UTR).

Methods: We generated dual luciferase reporter plasmids to study the influence of cytokines on the stability of transcripts associated with RA. The 3′-UTR sequences of RA-related genes (CXCL2, PIM1, CSF2, IL12B, IL1B, TNF, TNFRSF10B, HIF1A, ARHGEF2) with ARE were inserted into the 3′ end of the firefly luciferase gene in the pmirGLO Dual-Luciferase miRNA Target Expression Vector. Renilla luciferase in the plasmid was used as a control reporter for normalization. U2OS cells were transfected with these plasmids 2 hours before cytokine treatment. The transfected cells were stimulated with cytokines for 12 hours and were lysed using a passive lysis buffer for luciferase activity analyses with the Dual-Glo Luciferase Assay System and Infinite 200 PRO. TIA1, TIAR, TTP, or HuR were co-transfected with the reporter. The expression of CXCL2 mRNA in fibroblast-like synoviocytes (FLS) was examined by RT-PCR. In mRNA decay experiments, actinomycin D was used to stop RNA polymerase II dependent transcription in FLS.

Results: Various cytokine treatments affected the reporter luciferase activities. In particular, IL-1β and IL-17A increased the luciferase activities of the reporters harboring the 3′-UTR of CXCL2 mRNA in a dose-dependent manner. Addition of IL-1β remarkably upregulated the CXCL2 mRNA expression in FLS. The half-life of CXCL2 mRNA was significantly longer in IL-1β treated FLS (21.7 hours) than that in untreated FLS (3.3 hours). ARE-harboring mRNA is potentially regulated by RNA binding proteins including TIA1, TIAR, TTP, and HuR. Among these, co-transfection of TTP with the reporter plasmid suppressed the luciferase activity with the 3′UTR of CXCL2 mRNA.

Conclusion: Our data suggest that the metabolism of CXCL2 mRNA is stabilized by IL-1β, leading to a remarkable increase in CXCL2 mRNA in FLS. CXCL2 is a chemokine that is secreted from various cells for chemotactic attraction of polymorphonuclear leukocytes and is involved in the pathogenesis of infections and autoimmune diseases. Therefore, it is possible that IL-1β signaling stabilizes CXCL2 mRNA by regulating RNA binding proteins like TTP, for the recruitment of neutrophils at the inflamed joint.


Disclosure: S. Yamasaki, Eli Lilly and Company, 2; Y. Yoshida, None; E. Sugiyama, Eli Lilly and Company, 2,Bristol-Myers Squibb, 2,Pfizer Inc, 2,Chugai, 2.

To cite this abstract in AMA style:

Yamasaki S, Yoshida Y, Sugiyama E. Interleukin-1β Stabilize CXCL2 mRNA and Increase Its Expression [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/interleukin-1%ce%b2-stabilize-cxcl2-mrna-and-increase-its-expression/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interleukin-1%ce%b2-stabilize-cxcl2-mrna-and-increase-its-expression/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology